9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 601–700 of 958
Al-Dedah, R. M., Al-Ghanimi, H. H., Mashrea, D. S., & Alnasawi, T. H. (2023) · AIP conference proceedings · doi:10.1063/5.0149103 · Cited by 7
Guthrie, R. M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1742524 · Cited by 4
Chadwick, J., Sivamani, C., Lakshmi, S., Vishali, B., Swathi, N. L., Ayyasamy, L., Ganeshkumar, P., & Bagepally, B. S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08508-5 · Cited by 5
“Although both MBS and GLP-1 RAs are effective strategies for improving metabolic outcomes and reducing cardiovascular risk in the individual with obesity and T2DM, their risk-benefit profiles differ, and direct comparative evidence on long-term MACE and all-cause mortality is limited [25, 26].”
Sullivan, S. D., Freemantle, N., Gupta, R. A., Wu, J., Nicholls, C. J., Westerbacka, J., & Bailey, T. S. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.306 · Cited by 4
Wang, X., Wu, G., Shen, D., Zhang, X., & Yang, W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02128-y · Cited by 4
Canha, M. I., Ramos, G., Prata, R., Martins, P. L., Ramos, M. V., & Coimbra, J. M. G. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00989-2 · Cited by 4
“The introduction of insulin is associated with poorly controlled diabetes under oral medication [28], which can explain the higher proportion of complications of disease in this group.”
Liu, S. M., Wan, H., Nie, S., Cao, H., Liu, L., Liang, H., Xu, H., Liu, B., Chen, C., Liu, J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae281 · Cited by 4
Diabetes-inducing effects of bronchial asthma
Al‐Beltagi, M., Bediwy, A. S., Saeed, N. K., Bediwy, H. A., & Elbeltagi, R. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.97954 · Cited by 4
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin
Yoon, D. Y., Kim, J.-E., Cho, J., & Chung, J. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16358 · Cited by 4
Kaye, A. D., Lien, N., Vuong, C. A., Schmitt, M. H., Soorya, Y., Abubakar, B. A., Muiznieks, L., Embry, N. J., Siddaiah, H. B., Kaye, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.76101 · Cited by 6
Dagnew, S. B., Wondm, S. A., Tarekegn, G. Y., Kassaw, A. T., & Moges, T. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1450928 · Cited by 5
Chandru, S., Pramodkumar, T. A., Pradeepa, R., Muthukumar, S., Balasubramanyam, M., Bhuvaneshwari, R., Anjana, R. M., & Mohan, V. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.010 · Cited by 4
Marsellinda, E., & Ferilda, S. (2022) · Menara Ilmu · doi:10.31869/mi.v16i1.3406 · Cited by 4
Inns, S. J., Chen, A. C., Myint, H., Lilic, P., Ovenden, C., Su, H. Y., & Hall, R. M. (2023) · Nutrients · doi:10.3390/nu15183938 · Cited by 6
Su, R., Wan, L., Tao, Y., Zhu, M., Pu, J., Li, Z., Chen, Y., & Tang, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-75554-3 · Cited by 4
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
Mazzilli, R., Zamponi, V., Mancini, C., Giorgini, B., Golisano, B., Mikovic, N., Pecora, G., Russo, F., Martiradonna, M., Paravani, P., et al. (2025) · Endocrine · doi:10.1007/s12020-024-04149-9 · Cited by 4
HUNDAL, R. S., Kowalyk, S., Wakim, A. P., NIKKEL, C. C., Sink, J. H., & Doyle, M. (2020) · Medical Devices Evidence and Research · doi:10.2147/mder.s265869 · Cited by 4
Buitléir, C. D., Connor, E. O., Satti, M. M., Shaw, J., & Liew, A. (2020) · Diabetic Medicine · doi:10.1111/dme.14409 · Cited by 4
Ma, J., Zhang, B., Hou, J., & Peng, Y. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00955-2 · Cited by 4
Gameil, M. A., & El-Sebaie, A. H. (2020) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-020-00026-9 · Cited by 4
Emoto, N., Soga, A., Fukuda, I., Tanimura‐Inagaki, K., Harada, T., Koyano, H. M., Goto, R., & Sugihara, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s283591 · Cited by 4
Basu, S., Shao, H., Luo, J., Lipska, K. J., Suda, K. J., & Yudkin, J. S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107839 · Cited by 4
Uzoigwe, C., Radin, M. S., Hamersky, C. M., DeKoven, M., Holt, C., Karkare, S. U., & Polonsky, W. H. (2021) · Quality of Life Research · doi:10.1007/s11136-020-02753-6 · Cited by 4
Sia, H., Kor, C., Tu, S., Liao, P.-Y., & Chang, Y.-C. (2021) · PeerJ · doi:10.7717/peerj.11005 · Cited by 4
“A total of 24,473 patients with T2DM were enrolled in the Diabetes Care Management Program (DCMP) at the CCH Diabetes Care Center between January 2002 and December 2017.”
BackgroundInfluentialBoye, K. S., Lage, M. J., & Kiljanski, J. I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01051-9 · Cited by 5
Lee, J., Kim, H. S., Jung, C. H., Park, J., & Lee, W. J. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3466 · Cited by 4
Cui, J., Klepser, D. G., & McAdam‐Marx, C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.840 · Cited by 5
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 5
Liu, H., Wang, F., Ji, Y., Ma, T.-Y., Li, H., Linnebjerg, H., Chua, L., Tham, L. S., & Yu, Y. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1014 · Cited by 4
Loganadan, N. K., Huri, H. Z., Vethakkan, S. R., & Hussein, Z. B. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0059 · Cited by 4
Morales, C., Merino-Torres, J. F., Moreno-Moreno, P., Laínez, M. G. L., Tejado, I., Yoldi, A., Medina, S. G., Soto, A., Botana, M., Bellido, V., et al. (2022) · Drugs in Context · doi:10.7573/dic.2021-11-5 · Cited by 5
Narcisse, D. I., Katzenberger, D. R., & Gutierrez, J. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01677-6 · Cited by 4
Dardano, A., Aragona, M., Daniele, G., Miccoli, R., & Prato, S. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.847778 · Cited by 5
Hammerman, A., Azuri, J., Aboalhasan, E., & Arbel, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00506-5 · Cited by 5
Hejjaji, V., Martínez, J. J. G., Tang, F., Garnelo, J. B., Cooper, A., Medina, J., Mutiozabal, M. S., Khunti, K., Nicolucci, A., Shestakova, M. V., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14745 · Cited by 4
“strategy of intensive lifestyle modification in addition to GLMs that promote and support patients0 weight loss efforts.(10) Although intensive lifestyle modification is fundamental to losing”
MethodTsai, C.-J., & Tsao, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111915 · Cited by 4
Srinivasan, S., Wu, P., Mercader, J. M., Udler, M. S., Porneala, B., Bartz, T. M., Floyd, J. S., Sitlani, C. M., Guo, X., Haessler, J., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad123 · Cited by 4
Koskinas, K. C., Melmer, A., Steiner, N., Gübeli, A., Wilhelm, M., & Laimer, M. W. (2021) · Praxis · doi:10.1024/1661-8157/a003589 · Cited by 6
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_4 · Cited by 4
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
Taliercio, J. J., Thomas, G., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20190 · Cited by 4
“5,6 The authors thoroughly highlight the overwhelmingly benefi cial cardiovascular, kidney, and metabolic effects of this new class of medications that is taking many different medical specialties by storm.”
BackgroundLu, Y., Tang, H., Kotecha, P., Cho, H., Donahoo, W. T., Bian, J., & Guo, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15822 · Cited by 3
What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
Argano, C., Priola, L., Manno, F., & Corrao, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040900 · Cited by 5
Dai, J., Chang, J. J., Choi, J. M., Bullock, A. K., Manson, S. M., O’Connell, J., & Jiang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16021 · Cited by 3
“7,10,28 One study focusing on AI population found an increased use of any anti-diabetic medication and metformin, 16 aligning with our findings.”
Reıd, I. O. A., Osman, S. M., & Bakheet, S. M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i11.6895 · Cited by 3
“…six preferred treatment options should be considered: For patients with T2DM and established CVD, the antihyperglycemic regimen should include SGLT‑2 inhibitors or GLP‑1 receptor agonists with proven cardiovascular benefits, taking into account both drug-specific and patient-related factors 9 .”
Wu, Y., Xu, H., Wang, Y., Wang, X., & Wu, S. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s489408 · Cited by 3
Ba, T., Ren, Q., Gong, S., Li, M., Lian, H., Cai, X., Liu, W., Luo, Y., Zhang, S., Zhang, R., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70080 · Cited by 3
Zheng, M., Zhang, S., Wang, Y., Xie, N., Wang, X., Lv, J., Pang, X., & Xu, L. (2025) · Foods · doi:10.3390/foods14101785 · Cited by 3
“These mechanisms work together both inside and outside the pancreas to significantly reduce the risk of hypoglycemia due to their glucose-dependent nature [6].”
Wang, Q., Wu, H., Zhai, Z., Fang, D., Yang, C., Liu, L., Jia, X., Du, B., Lyu, Y., Zhang, M., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02721-4 · Cited by 3
Wantoro, A., Yuliana, A. F., Andini, D. Y. A., Awaliyani, I., & Caesarendra, W. (2025) · Jurnal Teknik Informatika (Jutif) · doi:10.52436/1.jutif.2025.6.4.5166 · Cited by 3
Hua, J., Wang, Q., Liu, Y., Luo, S., Shi, A., Yan, Z., Zhang, J., Gu, W., Zhu, L., Zhang, Y., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03173-5 · Cited by 4
“recommended for patients with T2DM who have established atherosclerotic cardiovascular disease (ASCVD) or are at high risk for CVD, CKD, or heart failure (HF) [17].”
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., Calliari, L. E., & Bertoluci, M. C. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00949-z · Cited by 4
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Ehrhardt, N. M., Fazeli, S., Rao, S., & AMDUR, R. L. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0025 · Cited by 3
Sugimoto, K., Tanaka, Y., Sozu, T., Nishiyama, H., Hoshino, T., Watanabe, Y., Tamura, A., Ohta, S., Yamazaki, T., Suzuki, S., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00814-0 · Cited by 3
Koliaki, C. C., Tzeravini, E., Papachristoforou, E., Severi, I., Eldeik, E., Karaolia, M., Noutsou, M., Thanopoulou, A. C., Kountouri, A., Balampanis, K., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00383 · Cited by 3
Lautsch, D., Iglay, K., Yang, L., Bansal, N., Markan, R. K., Kathe, N. J., & Rajpathak, S. N. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1816945 · Cited by 3
Ding, L., Sun, B., Xiao, X., & Kin, T. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1626484 · Cited by 3
“When the first-line therapy of metformin fails to be effective in glycemic control, it should be determined that whether the arteriosclerotic cardiovascular disease (ASCVD) is present, and if not present, the recommendation gives preference to a GLP-1RA or an SGLT-2i for obese T2D patients [11, 22].”
BackgroundThe Administration of Xultophy for Diabetic Patients on Hemodialysis
Fujikawa, T., Kato, Y., Bando, H., Kakutani, H., Kawata, T., Yamamoto, M., Wada, K., Ishikura, K., Shirai, Y., Narutaki, M., et al. (2020) · doi:10.36502/2020/droa.6172 · Cited by 7
Kobalava, Z. D., & Кохан, Е. В. (2020) · Kardiologiia · doi:10.18087/cardio.2020.9.n1274 · Cited by 4
Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
Petunina, N. A., Кузина, И. А., & Недосугова, Л. В. (2020) · Diabetes Mellitus · doi:10.14341/dm12487 · Cited by 4
Bedoya‐Joaqui, V., Gómez, N. B., Ortiz, R. C., Osorio-Toro, L. M., Muñoz-Lombo, J. P., Cifuentes, C. A. S., García, M. A. M., & Abreu-Lomba, A. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000319 · Cited by 5
Predictors of response to ambulatory pharmacist‐led diabetes care
Palka, S. J., Koeller, J. M., Davidson, D. A., Zeidan, A. R., & Reveles, K. R. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1394 · Cited by 3
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy
Butler, J., Bjurstrom, M., & Marceau, A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab045 · Cited by 3
Quality of Diabetes Care in the USA
Alencherry, B., & Bruemmer, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01503-5 · Cited by 4
WANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 4
Benevides, A. M. L. N., Rabelo, J. A. F., Soares, P. R. D. H., Marçal, E., Ferreira, L. F. D. A., & Medeiros, M. S. (2021) · Research Society and Development · doi:10.33448/rsd-v10i14.21823 · Cited by 4
Takeshita, Y., Kita, Y., Tanaka, T., Goto, H., Nakano, Y., Teramura, C., Enyama, Y., Takamura, T., & the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13749 · Cited by 3
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups
Bae, J. P., Liu, D., Chinthammit, C., KADZIOLA, Z. A., Boye, K. S., & Mather, K. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14678 · Cited by 3
Colin, I. M., Knoops, B., & Gérard, A.-C. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01114-2 · Cited by 3
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
Diabetes mellitus tipo 1: Una perspectiva para estudiantes de Ciencias de la Salud
Zambrano, D. Y., Gonzalez, M. A., Farfán-Cano, H. R., Farfán-Cano, G. G., & Moreira, K. M. C. (2022) · Revista Ecuatoriana de Ciencia Tecnología e Innovación en Salud Pública · doi:10.31790/inspilip.v4i3.247 · Cited by 3
Current insulinization trends in India
Hasnani, D., Saboo, B., Chaturvedi, A., Sikdar, M., Shankar, A., Choudhury, R., Saboo, B., Singh, N. M., Jha, S. K., & Chavda, V. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01123-x · Cited by 3
Bioactive lipids: Pharmaceutical, nutraceutical, and cosmeceutical applications
Fernandes, E., Lopes, C. M., & Lúcio, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824043-4.00006-3 · Cited by 3
Chawla, M. S., CHAWLA, P. M., Jethwani, P., Shah, K., & Reddy, S. (2023) · Clinics and Practice · doi:10.3390/clinpract13020045 · Cited by 3
Weeda, E. R., Ward, R. C., Gebregziabher, M., Axon, R. N., & Taber, D. J. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-023-01619-0 · Cited by 3
Applications of Turmeric Starch and Curcumin
Kırboğa, K. K., Tekin, B., & DEMİR, M. (2023) · Bayburt Üniversitesi Fen Bilimleri Dergisi · doi:10.55117/bufbd.1161709 · Cited by 4
Fernández-Crespo, S., Vázquez-Agra, N., Marques-Afonso, A.-T., Cruces‐Sande, A., Olmos, M. Á. M., Araújo‐Vilar, D., & Ameijeiras, Á. H. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.06.027 · Cited by 3
Shaikh, S. S., Vaidya, V., Gupta, A. K., Kulkarni, R., Joshi, A., Kulkarni, M., Sharma, V., & Revankar, S. Y. (2024) · Cureus · doi:10.7759/cureus.59850 · Cited by 3
Hall, R. M., Marshall, H. J., Parry‐Strong, A., Corley, B., & Krebs, J. D. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108778 · Cited by 3
Hyland, S. J., Max, M. E., Eaton, R. E., Wong, S. A., Egbert, S., & Blais, D. M. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae310 · Cited by 3
Aydemir, S., Aydın, S. Ş., Aksakal, E., Altınkaya, O., Özmen, M., & Birdal, O. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04454-1 · Cited by 3
Wahiduzzaman, M., Islam, M. S., Hossain, S., & Islam, S. M. S. (2025) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_216_24 · Cited by 3
Grabarczyk, T. R., & Wissman, N. K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020915791 · Cited by 3
Kumar, A., Sharma, S., Gupta, A., Dasgupta, A., Asirvatham, A. J., Talwalkar, P., Das, A., & Mohan, V. (2020) · Journal of Diabetology · doi:10.4103/jod.jod_59_20 · Cited by 3
GLP-1 Agonists Liraglutide Improved Vascular Endothelial Function in Type 2 Diabetes Rats
Li, X., Wei, W., Wang, Y., Zhang, X., Feng, X., & Liu, R. (2020) · doi:10.36502/2020/droa.6168 · Cited by 3
Chawla, M. S., Jain, S. M., Kesavadev, J., Makkar, B. M., Viswanathan, V., TIWASKAR, M. H., Sosale, A., Negalur, V. B., Modi, K. D., Gupta, M., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00979-8 · Cited by 3
Bhadada, S., Pal, R., Banerjee, M., & Kumar, A. S. (2020) · International Journal of Noncommunicable Diseases · doi:10.4103/jncd.jncd_69_20 · Cited by 3
Clinical studies on pharmacological treatment of hypertension in Japan
Kario, K., Hoshide, S., Yamamoto, K. I., Okura, A., & Rakugi, H. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00533-4 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Gavazza, M. L. N. D. B., Martins, E., & Ramalho, A. C. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000524 · Cited by 3
Trends in premature mortality from diabetes mellitus in Costa Rica in the period 2000–2020
Quesada, J. A., Carratalá‐Munuera, C., Carbonell-Soliva, Á., Aparicio, J. C. S., Fernández, J. G., Salazar‐Sánchez, L., Gil-Guillén, V. F., López‐Pineda, A., Nouni-García, R., & Orozco‐Beltrán, D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2135865 · Cited by 4
Nishimura, R., Takeshima, T., Iwasaki, K., & Aoi, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206016 · Cited by 3
Lee, C. G., & Cefalu, W. T. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4266 · Cited by 3
Luo, Z., Chou, O. H. I., Ng, Z. M. W., Chung, C. T., Chan, J. S. K., Chan, R. N. C., Lü, L., Zhu, T., Cheung, B. M. Y., Liu, T., et al. (2023) · medRxiv · doi:10.1101/2023.11.06.23298185 · Cited by 3
Insulin therapy in diabetic kidney disease
Liu, Y., Zhao, C., Xiong, X., Yang, M., & Sun, L. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2022-0006 · Cited by 2
Chen, M., Zhang, P., Zhao, Y. W., Duolikun, N., & Ji, L. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s386230 · Cited by 2
Metformin, Chlorpropamide, and Glibenclamide: Interactions with Metal Ions and Cyclodextrins
González-Barbosa, J., Hipólito-Nájera, A. R., Gómez‐Balderas, R., Rodríguez‐Laguna, N., & Moya‐Hernández, R. (2023) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x20666230117105443 · Cited by 2
Badarin, F. J. A., Yasine, L., Hijazi, R. A., Khalaf, S. A., Almahmeed, W. A., Manla, Y., & Bader, F. M. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1342 · Cited by 3
“…and American Diabetic Association (ADA) have updated their management guidelines for patients with diabetes and cardiovascular disease to include use of novel diabetic medications in diabetic patients and increased cardiovascular risk or those with established cardiovascular diseases [50, 51].”
BackgroundLi, L., Zhang, X., Zhang, T., Zeng, L., Lin, M., Li, Y., & Li, W. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s446855 · Cited by 2
“1,15,27 It’s widely recognized that FBG plays a significant role in influencing HbA1c levels.”
BackgroundNikolaidis, S., Kosmidis, I., Papadopoulos, S., Lioupi, A., Gandanidou, M., Gika, H., Dokoumetzidis, A., Theodoridis, G. A., & Mougios, V. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70208 · Cited by 2
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.